The test will help oncologists develop personalised treatment plans for patients with advanced ovarian cancer. Credit: Emily frost / Shutterstock.com.

Italy-based cancer centre IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’ has gone live on the Sophia Genetics platform for powering a new genomic test to treat advanced ovarian cancer.

This test employs next-generation sequencing (NGS) to recognise patients with homologous recombination deficiency (HRD), which is a predictive biomarker for therapy response.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

IRST advanced and predictive molecular diagnostics area head Daniele Calistri said: “The newly available HRD test will help our oncologists make data-based treatment plans that can potentially save the lives of patients who are diagnosed with, and treated for, advanced ovarian cancer at IRST.

“With the SOPHiA GENETICS technology, our team can move fast with the confidence that they are making strong decisions rooted in patient data.”

The SOPHiA DDM Platform leverages artificial intelligence (AI) and machine learning to analyse and interpret NGS data, streamlining the bioinformatics workflow and expediting assessment, interpretation, and reporting.

See Also:

This cloud-native application can analyse data from various sources, encompassing NGS, radiology, and pathology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test will help oncologists to develop personalised treatment plans for patients with advanced ovarian cancer.

SOPHiA GENETICS EMEA managing director Kevin Puylaert said: “The SOPHiA DDM Platform enables customers like IRST to quickly analyse sequencing data and, as we say at SOPHiA GENETICS, find the signal in the noise.

“We’re excited to continue expanding our work in Italy and helping health institutions like IRST equip their oncologists with the data needed to make precision medicine the gold standard of care.”